IP Library › Granted Patent US 11,591,565
Granted Patent B2
US 11,591,565 · App. 14/254,749 · Granted Feb 28, 2023

Media for stem cell proliferation and induction

Inventors: Cynthia Bamdad (Waltham, MA); Benoit Smagghe (Waltham, MA)
Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
C12N5/0607C12N5/0037C12N5/0056C12N5/0606C12N2500/90C12N2501/00C12N2501/10C12N2501/115C12N2501/15C12N2501/727C12N2501/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,591,565
App. No.
14/254,749
Granted
Feb 28, 2023
Kind
B2
Abstract

The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.

Claims (19)

1. A method for stimulating growth of stem or progenitor cells or for inducing cells to revert to a less mature state, the method comprising contacting cells with cell culture media that comprises a recombinant NME7 protein that comprises a nucleotide diphosphate kinase (NDPK) A domain and an NDPK B domain and does not comprise a targeting sequence.

2. The method according to claim 1 , wherein the stem or progenitor cells are grown or the cells are induced to revert to the less mature state on a surface coated with anti-MUC1* antibody.

3. The method according to claim 1 , wherein the recombinant NME7 is the only growth factor in the cell culture media.

4. The method according to claim 1 , wherein the cell culture media does not comprise basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF-beta).

5. The method according to claim 1 , wherein the cells are mature, somatic or progenitor cells.

6. The method according to claim 1 , wherein the cells are human cells.

7. The method according to claim 1 , wherein the cell culture media is free of serum.

8. The method according to claim 1 , wherein the cell culture media further comprises insulin, selenium, transferrin, L ascorbic acid, or one or more non-essential amino acids.

9. The method according to claim 1 , wherein the recombinant NME7 is characterized by a molecular weight of about 25 to 33 kilodaltons (kDa).

10. The method according to claim 1 , wherein the recombinant NME7 protein is characterized by a molecular weight of about 30 kilodaltons (kDa).

11. The method according to claim 1 , wherein the recombinant NME7 has a molecular weight of about 31 kilodaltons (kDa).

12. The method according to claim 1 , wherein the recombinant NME7 is characterized by a molecular weight of about 33 kilodaltons (kDa).

13. The method according to claim 1 , wherein the recombinant NME7 comprises the amino acid sentience of SEQ ID NO: 39 41 59 or 61.

14. The method according to claim 1 , wherein the recombinant NME7 comprises an alternative splice isoform having an amino acid sequence of SEQ ID NO: 39, 41, 59 or 61.

15. The method according to claim 1 , wherein the cell culture media further comprises an inhibitor of a rho associated kinase.

16. The method according to claim 1 , wherein the cell culture media further comprises an activator of one or more signaling proteins in the PBK or RAC pathway.

17. The method according to claim 1 , wherein the cell culture media further comprises an activator of one or more signaling proteins in the PBK or RAC pathway in the absence of a rho kinase inhibitor.

18. The method according to claim 1 , wherein the cell culture media further comprises a nucleic acid that suppresses expression of NME1 or NME2.

19. The method according to claim 1 , wherein the recombinant NME7 has superior high yield expression of the soluble, properly folded protein in E. coli compared with native NME7.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2017
From: BAMDAD, CYNTHIA; SMAGGHE, BENOIT
To: MINERVA BIOTECHNOLOGIES CORPORATION
Reel/Frame 042310/0525 →
Continuity (15)
Continuation In Part PCTUS2012060684 · Oct 17, 2012
Provisional Application 61693712 · Aug 27, 2012
Provisional Application 61684654 · Aug 17, 2012
Provisional Application 61683155 · Aug 14, 2012
Provisional Application 61679021 · Aug 2, 2012
Provisional Application 61677442 · Jul 30, 2012
Provisional Application 61675264 · Jul 24, 2012
Provisional Application 61675292 · Jul 24, 2012
Provisional Application 61673617 · Jul 19, 2012
Provisional Application 61671558 · Jul 13, 2012
Provisional Application 61671588 · Jul 13, 2012
Provisional Application 61622422 · Apr 10, 2012
Provisional Application 61618578 · Mar 30, 2012
Provisional Application 61548199 · Oct 17, 2011
Related Publication 20150017726A1 · Jan 15, 2015
Cited By (3)
US 12,195,728 US 12,415,868 US 12,491,259